Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

A second chikungunya vaccine may soon be available for travelers, officials say TUESDAY, May 13, 2025 (HealthDay News) — U.S.

The FDA and CDC recommended the pause while the government looks into possible side effects. Also: RFK Jr. raises eyebrows after swimming with his grandkids in a contaminated creek; President Donald ...

Federal health officials are advising Americans aged 60 and older to avoid the chikungunya vaccine Ixchiq amid an ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17 SAEs worldwide (including two deaths) in ...

The ACIP voted to recommend a precaution related to the use of Ixchiq in patients aged 65 years and older ... Chief Medical Officer of Valneva. “We encourage providers to assess the benefit/risk of ...